First mRNA treatment tested for rare hormone disorder
NCT ID NCT07197450
Summary
This early-stage study is testing a new mRNA drug called XH02 for adults with hypoparathyroidism, a condition where the body doesn't make enough parathyroid hormone. The drug is designed to instruct the body to produce this missing hormone after being given through an IV. The main goal is to check if the treatment is safe and if it can help control calcium levels better than current standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, 100730, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.